Segment & Geographic Data
Quant-Grade Normalized Data
API & CSV Delivery
Beone Medicines Ltd's Business Segments
Beone Medicines Ltd's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Reportable Segments
13
Largest Segment
Brukinsa
Total Revenue
$ 1,890
Regions Reported
2
API endpoints for this dataset
https://api.csimarket.com/api/v1/companies/ONC/segments
https://api.csimarket.com/api/v1/companies/ONC/geographic
https://api.csimarket.com/api/v1/companies/ONC/exposure
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Connect Your AI Assistant
Revenue Share by Reportable Segment -
- Brukinsa0%
- Tevimbra35.9%
- Xgeva15.9%
- Product11.6%
- Blincyto5.8%
- Other3.6%
- Amgen Royalty Revenue3.3%
- Baituowei2.9%
- Kyprolis2.4%
- Pobevcy1.7%
- Other Revenue U S - total revenue0.9%
- Other Revenue0.5%
- Collaboration Other0.3%
Revenue by Reportable Segment -
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Brukinsa | $ 3,733 | - |
| Tevimbra | $ 678 | 35.9% |
| Xgeva | $ 300 | 15.9% |
10 more segments available
Sign in to unlock the full Beone Medicines Ltd dataset.
Revenue Share by Region -
- Europe12.7%
- All Other Countries Except, the United States of America, China, and Europe4.5%
Revenue by Geographic Region -
| Region | Revenue (Millions) | % of Total |
|---|---|---|
| Europe | $ 240 | 12.7% |
| All Other Countries Except, the United States of America, China, and Europe | $ 86 | 4.5% |
Revenue by Product & Service Category -
- Product98.2%
- Brukinsa73.6%
- Tevimbra12.9%
- Xgeva5.6%
- Blincyto2.1%
- Other Revenue1.8%
- Other1.6%
- Baituowei1.2%
- Kyprolis0.7%
- Pobevcy0.6%
Revenue by Product & Service Category -
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Product | $ 1,855 | 98.2% |
| Brukinsa | $ 1,391 | 73.6% |
| Tevimbra | $ 243 | 12.9% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
7 more categories available
Sign in to unlock the full Beone Medicines Ltd dataset.
Annual Results
Revenue Share by Reportable Segment -
- Brukinsa0%
- Tevimbra35.9%
- Xgeva15.9%
- Product11.6%
- Blincyto5.8%
- Other3.6%
- Amgen Royalty Revenue3.3%
- Baituowei2.9%
- Kyprolis2.4%
- Pobevcy1.7%
- Other Revenue U S - total revenue0.9%
- Other Revenue0.5%
- Collaboration Other0.3%
Revenue by Reportable Segment -
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Brukinsa | $ 3,733 | - |
| Tevimbra | $ 678 | 35.9% |
| Xgeva | $ 300 | 15.9% |
10 more segments available
Sign in to unlock the full Beone Medicines Ltd dataset.
Description of Beone Medicines Ltd
The registrant is a global oncology company focused on discovering and developing cancer treatments. In 2025, it reported approximately $5.3 billion in global revenue, representing a 40.2% increase from the prior year, and a net income of $286.9 million. The company specializes in hematology, particularly chronic lymphocytic leukemia (CLL), with three key mechanisms of action: BRUKINSA®, a Bruton’s tyrosine kinase (BTK) inhibitor; sonrotoclax, a B-cell lymphoma 2 (BCL2) inhibitor approved in China for relapsed/refractory mantle cell lymphoma (MCL) and CLL; and BTK chimeric degradation activation compound (BTK-CDAC), BGB-16673, designed to degrade both wildtype and mutant BTK. BRUKINSA is approved in over 75 markets and leads the global market in B-cell malignancies. The company is conducting multiple Phase 3 trials, including combinations of BRUKINSA and sonrotoclax. It also has a solid tumor pipeline with five new molecular entities in clinical development targeting cancers such as breast, lung, and gastrointestinal. The company employs nearly 6,000 clinical and manufacturing staff, operating a global clinical development model that reduces reliance on contract research organizations. Incorporated in Switzerland, it has subsidiaries in the U.S., China, the UK, and Australia, and employs approximately 12,000 people worldwide.
The company operates a single reportable segment focused on pharmaceutical products. The Chief Executive Officer reviews consolidated results for resource allocation and performance evaluation of the company as a whole.